Latest Breaking News On - Archerdx inc - Page 16 : comparemela.com
Global Hemato-Oncology Testing Market Report 2021: Market to Reach $5 4 Billion by 2027 - U S Market is Estimated at $603 Million, While China is Forecast to Grow at 17 6% CAGR
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Worldwide Genomic Cancer Panel and Profiling Industry to 2025 - Featuring Anchor, Bioarray Genetics and Burning Rock Among Others
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Worldwide Genomic Cancer Panel and Profiling Industry to 2025 - Featuring Anchor, Bioarray Genetics and Burning Rock Among Others
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Hematologic Malignancies Testing Market Share, Size, & Trends Analysis Report, Region, and Segment Forecasts, 2020 – 2028
emergenMay 23, 2021 1
The global Hematologic Malignancies Testing Market is forecasted to be worth USD 5.45 Billion by 2027, according to a current analysis by Emergen Research. In March 2020, Sysmex Corporation received japan marketing clearance for BGI Genomics Coronavirus kit distribution. This initiative will strengthen its position in Japan. During the forecast timeline, the Next-generation sequencing segment will hold the largest market with a CAGR of 14.8%. In next-generation sequencing, the steadily developing cohort of technologies allowing the detection of gene variations present in Rna and DNA. In the case of hematologic malignancies, such differences provide diagnostic relevance.
7 Molecular Diagnostics Recent Developments
7.1 Recent Developments - Importance and How to Use This Section
7.1.1 Importance of These Developments
7.1.2 How to Use This Section
7.2 Nucleix to Invest in Early-Stage Lung Cancer Dx
7.3 Invitae to Acquire Genosity for $200M
7.4 Bio-Techne Obtains CE Mark for Exosomal Liquid Biopsy Prostate Test
7.5 Agilent Technologies to Acquire Liquid Biopsy Firm Resolution Bioscience
7.6 Natera Revenues Grow 35 Percent
7.7 AnchorDx Closes $40M Financing Round
7.8 Exact Sciences Strategy for End-to-End Cancer Testing
7.9 Genomics England: Whole Genome Sequencing for Cancer Patients to Launch
7.10 Singlera Genomics Closes $150M Funding for Cancer Screening
7.11 Biocartis GeneproDx, Endpoint Health Collaborate on Tests for Idylla Platform